Header graphic for print
Dangerous Drugs & Medical Devices News & Commentary on Prescription Drug & Medical Device Lawsuits

Jared Fink

Jared Fink Jared Fink is the firm’s pharmacovigilance specialist. He is a graduate of the College of Wooster and has a strong background in scientific research and writing. His full biography is here.

Posts by Jared Fink

Autism, developmental delay risk raised 300% with SSRI exposure before birth

Posted in SSRI Birth Defects

This past April, a piece by R.A. Harrington and a team from Johns Hopkins Bloomberg School of Public Health published in Pediatrics titled “Prenatal SSRI Use and Offspring With Autism Spectrum Disorder or Developmental Delay.” further illustrates the link between prenatal exposure to selective serotonin reuptake inhibitor drugs (SSRIs) and increased risk for autism and… Continue Reading

Study finds some babies more likely to have SSRI birth defects than others

Posted in SSRI Birth Defects

Last summer, Developmental Psychobiology published a piece by S. Brummelte and a team from University of British Columbia (Vancouver) titled “Antidepressant use during pregnancy and serotonin transporter genotype (SLC6A4) affect newborn serum reelin levels.” exploring contributing genetic factors to susceptibility for SSRI-induced birth defects.  To-date, a number of studies have shown that in utero exposure… Continue Reading

2005 – Higher rate of birth defects with Depacon in pregnancy

Posted in Depacon / Depakene / Depakote

A 2005 article in Acta Neurologica Scandinavica by F.J. Vajda and a team from University of Melbourne (Australia) titled “Maternal valproate dosage and foetal malformations.” further elucidates the connection between prenatal exposure to antiepileptic drugs like Depacon and birth defects.  Because the manufacturers (Abbott Laboratories) failed to warn women of this risk in light of… Continue Reading

Depacon Doubles Risk for Birth Defects (At Least)

Posted in Depacon / Depakene / Depakote

Another article demonstrating that prenatal exposure to antiepileptic drugs containing valproate like Depacon is associated with birth defects, “Valproate and the risk for congenital malformations: Is formulation and dosage regime important?” was published in the April, 2012 edition of the medical journal Seizure by E. Mawhinney et al. of Belfast, UK. In light of warnings… Continue Reading

2- to 3-fold increase in birth defects linked to Depacon / Depakote / Depakene

Posted in Depacon / Depakene / Depakote

In 2005, a team of researchers from The University of Pavia (Pavia, Italy) published a study in Lancet Neurology titled “Birth defects after prenatal exposure to antiepileptic drugs.”, yet again demonstrating that in utero exposure to Depacon, Depakene, and Depakote (antiepileptic drugs containing valproate) is linked to an increased risk for spina bifida, other neurological… Continue Reading

2012 – Babies with Depakote exposure more likely to have malformations

Posted in Depacon / Depakene / Depakote

Published in the January, 2012 edition of Journal of Clinical Neuroscience, an article by F.J. Vajda titled “Teratogenicity of the newer antiepileptic drugs–the Australian experience.” provides important insight into the connection between valproate-containing antiepileptic drugs such as Depacon, Depakene, and Depakote (Abbott Laboratories) and birth defects including spina bifida and developmental disorders including Autism. Reviewing… Continue Reading

Study links maternal SSRIs and childhood autism

Posted in SSRI Birth Defects

A New England Journal of Medicine article published in December, 2013 by A. Hviid et al. titled “Use of selective serotonin reuptake inhibitors during pregnancy and risk of autism.” demonstrates further the connection between prenatal exposure to a mother’s selective serotonin reuptake inhibitor drugs (SSRIs) and increased risk for congenital malformations and autism. Hviid et… Continue Reading

Depakote raises risk for birth defects 2- to 4-fold

Posted in Depacon / Depakene / Depakote

In recent years, dozens of studies have linked prenatal exposure to the antiepileptic drugs containing valproate (Depacon, Depakene, and Depakote) with birth defects including spina bifida, and developmental disorders such as Autism.  Since the manufacturer of these drugs, Abbott Laboratories, failed time and again to warn women of these risks, Depacon birth defect lawsuits have… Continue Reading

Huge increase in birth defect risk with prenatal Depacon, AED exposure

Posted in Depacon / Depakene / Depakote

Titled “Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population-based register study.”, a study by K. Wide et al. (2004) further demonstrates knowledge in the medical community that in utero exposure to antiepileptic drugs (AEDs) containing valproate (Depacon, Depakene, Depakote, and others) is linked… Continue Reading

Offspring maladaptive with in utero SSRI epxosure

Posted in SSRI Birth Defects

Today, looking through PubMed Health, a medical literature database curated by the United States National Library of Medicine and The National Institutes of Health, I found another article linking poor neonatal outcomes and  to birth defects prenatal exposure to maternal selective serotonin reuptake inhibitor drugs (SSRIs).  This article, titled “Developmental effects of SSRIs: lessons learned… Continue Reading

2003 – In Utero AED Exposure Linked to Birth Defects Far Above Background Rate

Posted in Depacon / Depakene / Depakote

In September, 2003, a team from St. Vincent’s Hospital (Melbourne, Australia) published a piece in Journal of Clinical Neuroscience titled “The Australian registry of anti-epileptic drugs in pregnancy: experience after 30 months.”  That article, by F.J. Vajda et al., further explored the risks of prenatal exposure to antiepileptic drugs containing valproate, such as Depacon, Depakene,… Continue Reading

1999 – Researchers find Depacon, Depakene, and Depakote linked to major congenital abnormalities

Posted in Depacon / Depakene / Depakote

Published in a 1999 edition of Annals of Neurology, an article by E.B. Samrén et al. titled “Antiepileptic drug regimens and major congenital abnormalities in the offspring.” provides important insight into the risks of prenatal exposure to antiepileptic drugs (AEDs), something that has been demonstrated to greatly increase the rate of spina bifida, other neurological… Continue Reading

Prenatal exposure to Depacon, Depakene, Depakote linked to lower intelligence in children

Posted in Depacon / Depakene / Depakote

Over the past ten years or so, dozens of studies have been published linking prenatal exposure to the antiepileptic drugs Depacon, Depakene, and Depakote (Abbott Laboratories, Inc.) with birth defects.  Here, I will summarize one such study, published by R. Banach and a team from McMaster University in Ontario Canada.  This study was titled “Long-term… Continue Reading

1997 – Team finds Depacon / Depakene / Depakote to lift malformation risk up to 700%

Posted in Depacon / Depakene / Depakote

Back in 1997, a team of Dutch medical researchers led by E.B. Samrén published an article titled “Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy.” in Epilepsia.  That article aimed to “To quantify the risks of intrauterine antiepileptic drug… Continue Reading

Birth defects risk 2-3 times higher with Depacon exposure

Posted in Depacon / Depakene / Depakote

From a team of Swedish researchers, an article appearing in the November, 2009 edition of Neurologic Clinics titled “Teratogenic effects of antiepileptic medications.” provides important insight into the connection between prenatal exposure to epilepsy drugs Depacon, Depakene, and Depakote and cardiovascular and neurological birth defects.  Because of a failure to warn, class-action Depacon lawsuits have… Continue Reading

2011 – Depakote only drug to lift birth defect risk in polytherapy

Posted in Depacon / Depakene / Depakote

A study titled “Fetal effects of anticonvulsant polytherapies: different risks from different drug combinations.” by L.B. Holmes and a team from MassGeneral Hospital for Children (Boston, MA) published in the October, 2011 edition of Archives of Neurology further explores the link between in utero exposure to epilepsy drugs containing valproate (Depacon and other drugs by… Continue Reading

New England Journal of Medicine: Depacon Causes Defects, Decreased Cognitive Function

Posted in Depacon / Depakene / Depakote

Titled “Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs.”, an article by K.J. Meador and a team from Emory University published in the April, 2009 edition of New England Journal of Medicine provides further insight into the adverse effects of prenatal exposure to antiepileptic drugs containing valproate, the active chemical… Continue Reading

Depacon, Depakote, and Depakene carry risk for birth defects at 6.7%

Posted in Depacon / Depakene / Depakote

In February of this year, E. Campbell and a team from Royal Victoria Hospital (Belfast, UK) published a piece in Journal of Neurology, Neurosurgery, and Psychiatry titled “Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers.” further demonstrating the link between exposure to maternal epilepsy… Continue Reading

Reduced cognitive ability linked to prenatal Depacon / Depakene / Depakote exposure

Posted in Depacon / Depakene / Depakote

In March, 2013, a medical research team led by K.J. Meador published an article in Lancet Neurology titled “Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study.”.  This team from Emory University (Atlanta) aimed to “We aimed to assess effects of commonly used antiepileptic drugs on cognitive… Continue Reading

Depakote linked to birth defects, poor neonatal development

Posted in Depacon / Depakene / Depakote

In recent years, a number of independent medical research teams have determined that prenatal exposure to antiepileptic drugs branded Depacon, Depakene, and Depakote is linked to increased risk for birth defects.  Here, I will discuss research from one such team led by G. Veiby of The University of Bergen, Norway, specifically, an article titled “Pregnancy,… Continue Reading

Increased risk for neonatal morbidity linked to prenatal SSRI exposure

Posted in SSRI Birth Defects

In October, 2012, a team of Swedish researchers (University of Lund) led by B. Källén published an article in Journal of Clinical Psychopharmacology titled “Neonatal complications after maternal concomitant use of SSRI and other central nervous system active drugs during the second or third trimester of pregnancy.”, exploring the range of neonatal complications linked to… Continue Reading

2013 – More researchers find serious risks with antidepressants in pregnancy

Posted in Prozac Birth Defects, SSRI Birth Defects

Titled “The risks of selective serotonin reuptake inhibitor use in infertile women: a review of the impact on fertility, pregnancy, neonatal health and beyond.”, a piece appearing in the January, 2013 edition of Human Reproduction by A.D. Domar and a team from Harvard Medical School provides important insight into the link between gestational exposure to… Continue Reading

Heart defects linked to prenatal Prozac exposure

Posted in Prozac Birth Defects, SSRI Birth Defects

In July, 2008, a team of researchers from The Netherlands led by CW Noorlander published a study titled “Modulation of serotonin transporter function during fetal development causes dilated heart cardiomyopathy and lifelong behavioral abnormalities.” in PLoS One.  This article delves further into the link between prenatal exposure to a mother’s selective serotonin reuptake inhibitor drug… Continue Reading

SSRIs in pregnancy linked to increased weight later in child’s life

Posted in SSRI Birth Defects

A 2012 in Reproductive Toxicology by L.E. Grzeskowiak at a team from University of South Australia  (Adelaide) titled “Long term impact of prenatal exposure to SSRIs on growth and body weight in childhood: evidence from animal and human studies.” explores the link between a baby’s exposure to maternal selective serotonin reuptake inhibitor drugs (SSRIs) and… Continue Reading